Global Antibody Drug Conjugates Contract Manufacturing Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Global Antibody Drug Conjugates Contract Manufacturing Market 2023 by Company, Regions, Type and Application, Forecast to 2029

According to our (Global Info Research) latest study, the global Antibody Drug Conjugates Contract Manufacturing market size was valued at USD 2909.1 million in 2022 and is forecast to a readjusted size of USD 9320.3 million by 2029 with a CAGR of 18.1% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Key global companies of Antibody Drug Conjugates Contract Manufacturing (ADC) include Lonza, Merck, Recipharm, Thermo Fisher, AbbVie, Piramal Pharma Solutions, Catalent, Sterling Pharma Solutions and Curia. The top three players are Lonza, Merck and Recipharm, which together account for about 50% of the global market share. The largest player is Lonza Group. From the production side, the global players are mainly concentrated in North America and Europe. North America accounts for about 35% of the global market share. In terms of type, IgG1 dominates the global antibody drug conjugate contract manufacturing market. In terms of application, solid tumor applications account for more than half of the market.

ADCs are mainly composed of three parts: antibodies, linkers, and cytotoxic loads. They are a type of bioactive cytotoxic drugs that are linked to monoclonal antibodies through chemical bonds and use monoclonal antibodies as carriers to target and transport cytotoxic drugs to target cells. Complex that works. The design concept of ADC was first proposed by Paul Ehrlich in the early 20th century. In 2000, the U.S. Food and Drug Administration (FDA) approved the first ADC drug, Mylotarg® (gemtuzumab ozogamicin), for the treatment of acute myeloid myelopathy in adults. Leukemic cell lines, marking the beginning of the era of ADC-targeted cancer therapy.

This report is a detailed and comprehensive analysis for global Antibody Drug Conjugates Contract Manufacturing market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Antibody Drug Conjugates Contract Manufacturing market size and forecasts, in consumption value ($ Million), 2018-2029

Global Antibody Drug Conjugates Contract Manufacturing market size and forecasts by region and country, in consumption value ($ Million), 2018-2029

Global Antibody Drug Conjugates Contract Manufacturing market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029

Global Antibody Drug Conjugates Contract Manufacturing market shares of main players, in revenue ($ Million), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Antibody Drug Conjugates Contract Manufacturing

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Antibody Drug Conjugates Contract Manufacturing market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Lonza Group, Merck KGaA, Recipharm, Thermo Fisher Scientific and Abbvie, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation

Antibody Drug Conjugates Contract Manufacturing market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
IgG1
IgG4

Market segment by Application
Solid Tumors
Hematological Malignancies

Market segment by players, this report covers
Lonza Group
Merck KGaA
Recipharm
Thermo Fisher Scientific
Abbvie
Piramal Pharma Solutions
Catalent
Sterling Pharma Solutions
Curia
Novasep
Ajinomoto Bio-Pharma Services
BSP Pharmaceuticals
Cerbios-Pharma
Goodwin Biotechnology

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Antibody Drug Conjugates Contract Manufacturing product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Antibody Drug Conjugates Contract Manufacturing, with revenue, gross margin and global market share of Antibody Drug Conjugates Contract Manufacturing from 2018 to 2023.

Chapter 3, the Antibody Drug Conjugates Contract Manufacturing competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Antibody Drug Conjugates Contract Manufacturing market forecast, by regions, type and application, with consumption value, from 2024 to 2029.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War

Chapter 12, the key raw materials and key suppliers, and industry chain of Antibody Drug Conjugates Contract Manufacturing.

Chapter 13, to describe Antibody Drug Conjugates Contract Manufacturing research findings and conclusion.